The Kit Signaling Pathway As a Therapeutic Target in Melanoma

Investigator: Boris C. Bastian, MD, PhD
Sponsor: American Skin Association

Location(s): United States


Recently, genetic alterations activating the receptor tyrosine kinase KIT have been demonstrated in some types of melanoma. KIT mutations can be successfully targeted by approved drugs in other cancers. Emerging evidence suggests that melanomas with KIT activation may also respond to KIT inhibitors that are already in clinical use.